PMID- 26677330
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20151217
LR  - 20201001
IS  - 1176-6328 (Print)
IS  - 1178-2021 (Electronic)
IS  - 1176-6328 (Linking)
VI  - 11
DP  - 2015
TI  - Milnacipran treatment and potential biomarkers in depressed patients following an 
      initial SSRI treatment failure: a prospective, open-label, 24-week study.
PG  - 3031-40
LID - 10.2147/NDT.S95067 [doi]
AB  - BACKGROUND: We assessed the effect of switching patients with major depressive 
      disorder to milnacipran following an initial selective serotonin reuptake 
      inhibitor treatment failure, and explored potential biomarkers in their blood. 
      METHODS: We conducted a prospective, open-label, 24-week trial. Depression was 
      assessed with the 17-item Hamilton Depression Rating Scale. Patients showing a 
      >/=50% reduction in Hamilton Depression Rating Scale scores from baseline to final 
      visit were considered responders. Regarding adverse effects (AEs), 
      moderate-to-severe AEs were specifically identified as effects that required any 
      medical treatment or that induced treatment withdrawals. We also measured blood 
      levels of various molecules including inflammatory cytokines. RESULTS: Of the 30 
      participants who enrolled, 17 completed this study. The responder rate was 30% 
      (n=10). Baseline serum levels of interleukin-6 (Z=-2.155; P=0.031) and 
      interleukin-8 (Z=-2.616; P=0.009) were significantly higher when 
      moderate-to-severe AEs were present (n=13 patients with moderate-to-severe AEs). 
      Serum levels of macrophage inflammatory protein-1beta showed a significant 
      continuous decrease from the baseline level (Friedman's test: chi (2)=23.9, df=4, 
      P<0.001) only in non-responders. CONCLUSION: These results demonstrate that serum 
      levels of interleukin-6, interleukin-8, and macrophage inflammatory protein-1beta as 
      potential blood biomarkers could be utilized to identify the responsiveness of 
      patients to serotonin and norepinephrine reuptake inhibitor like milnacipran, or 
      to identify those patients who may experience AEs strong enough to warrant 
      discontinuation of treatment.
FAU - Hashimoto, Tasuku
AU  - Hashimoto T
AD  - Department of Psychiatry, Chiba University Graduate School of Medicine, Chiba, 
      Japan ; Sodegaura Satsukidai Hospital, Chiba University, Chiba, Japan.
FAU - Sakurai, Daiji
AU  - Sakurai D
AD  - Department of Psychiatry, Chiba University Graduate School of Medicine, Chiba, 
      Japan.
FAU - Oda, Yasunori
AU  - Oda Y
AD  - Department of Psychiatry, Chiba University Graduate School of Medicine, Chiba, 
      Japan.
FAU - Hasegawa, Tadashi
AU  - Hasegawa T
AD  - Department of Psychiatry, Chiba University Hospital, Chiba, Japan.
FAU - Kanahara, Nobuhisa
AU  - Kanahara N
AD  - Division of Medical Treatment and Rehabilitation, Centre for Forensic Mental 
      Health, Chiba University, Chiba, Japan.
FAU - Sasaki, Tsuyoshi
AU  - Sasaki T
AD  - Department of Psychiatry, Chiba University Hospital, Chiba, Japan.
FAU - Komatsu, Hideki
AU  - Komatsu H
AD  - Department of Psychiatry, Chiba University Hospital, Chiba, Japan ; Choshi Kokoro 
      Clinic, Chiba, Japan.
FAU - Takahashi, Junpei
AU  - Takahashi J
AD  - Department of Psychiatry, Chiba University Graduate School of Medicine, Chiba, 
      Japan ; Choshi Kokoro Clinic, Chiba, Japan.
FAU - Oiwa, Takahiro
AU  - Oiwa T
AD  - Mobara Shinkeika Hospital, Chiba, Japan.
FAU - Sekine, Yoshimoto
AU  - Sekine Y
AD  - Division of Medical Treatment and Rehabilitation, Centre for Forensic Mental 
      Health, Chiba University, Chiba, Japan ; Choshi Kokoro Clinic, Chiba, Japan.
FAU - Watanabe, Hiroyuki
AU  - Watanabe H
AD  - Department of Psychiatry, Chiba University Graduate School of Medicine, Chiba, 
      Japan.
FAU - Iyo, Masaomi
AU  - Iyo M
AD  - Department of Psychiatry, Chiba University Graduate School of Medicine, Chiba, 
      Japan ; Department of Psychiatry, Chiba University Hospital, Chiba, Japan.
LA  - eng
PT  - Journal Article
DEP - 20151210
PL  - New Zealand
TA  - Neuropsychiatr Dis Treat
JT  - Neuropsychiatric disease and treatment
JID - 101240304
PMC - PMC4677766
OTO - NOTNLM
OT  - adverse effects
OT  - biomarkers
OT  - cytokines
OT  - major depressive disorder
OT  - milnacipran
EDAT- 2015/12/18 06:00
MHDA- 2015/12/18 06:01
PMCR- 2015/12/10
CRDT- 2015/12/18 06:00
PHST- 2015/12/18 06:00 [entrez]
PHST- 2015/12/18 06:00 [pubmed]
PHST- 2015/12/18 06:01 [medline]
PHST- 2015/12/10 00:00 [pmc-release]
AID - ndt-11-3031 [pii]
AID - 10.2147/NDT.S95067 [doi]
PST - epublish
SO  - Neuropsychiatr Dis Treat. 2015 Dec 10;11:3031-40. doi: 10.2147/NDT.S95067. 
      eCollection 2015.